Prostate Cancer Surgery Lagged for Black Men During Pandemic
Black men less likely than White men to undergo prostatectomy despite similar COVID-19 risk factors, biopsy Gleason grade groups.
Prostate Cancer News
PROSTATE CANCER ADVISOR
Prostate Cancer News
Ipatasertib Plus Abiraterone: A New Potential Treatment for Metastatic Castration-Resistant Prostate Cancer With PTEN Loss
The combination improved progression-free survival.
Nomograms May Aid Patient Selection for 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
The nomograms predicted overall and progression-free survival.
MRI Can Avoid Unnecessary Prostate Biopsies Among Screened Men
In a trial of men who volunteered for PSA screening, detection of clinically insignificant tumors and benign findings were reduced when prostate biopsy was performed only in those with positive MRI results.
Mortality Risk Factors in Patients With Cancer and COVID-19 Identified
Investigators zero in on mortality risk factors in patients with cancer who contract COVID-19.
Pathologic Outcomes in Prostate Cancer Cases Worsened During Pandemic
Compared with before the pandemic, men undergoing radical prostatectomy during the pandemic were more likely to have extraprostatic disease, according to investigators.
PSMA-PET/CT May Detect Prostate Cancer More Accurately Than mpMRI
Early results support a fully-powered trial of 18F-PSMA PET/CT for prostate cancer detection, according to the investigators.
Apalutamide Prolongs Survival in mCSPC Regardless of Disease Volume
A final analysis of the TITAN trial shows that apalutamide vs placebo added to ADT significantly lowers the risk of death and castration-resistant disease in men with metastatic castration-sensitive prostate cancer.
Obesity Linked to Lower Death Risk in mCRPC
Obesity in men with metastatic castration-resistant prostate cancer is associated with decreased risks for all-cause and cancer-specific mortality compared with overweight and normal-weight men.
mpMRI Misses Few Significant Prostate Cancers in Re-Biopsied Men
Study findings lend support to using mpMRI for prostate cancer detection.
ASCO and Friends: Cancer Patients Should Be Included in COVID-19 Vaccine Trials
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
Active Surveillance for Intermediate-Risk Prostate Cancer Linked With Lower Survival
Survival curves separated as early as 4 to 5 years after initiation of active surveillance or active treatment, investigators reported.
Race May Influence Treatment Receipt in Prostate Cancer
In high treatment benefit category, Black men less likely to receive definitive treatment than non-Black men.
Apalutamide Reduces the Risk of Death in Metastatic Castration-Sensitive Prostate Cancer
Adding apalutamide to androgen deprivation therapy improved survival and delayed progression.
Metformin Possibly Beneficial in Advanced Prostate Cancer
In a randomized controlled study, adding metformin to androgen deprivation therapy for low-tumor-volume metastatic hormone-sensitive prostate cancer significantly delayed development of castration-resistant disease.
Adjuvant Radiation May Provide a Survival Benefit Over Salvage Radiation in High-Risk Prostate Cancer
Low-risk patients did not appear to benefit from adjuvant radiation.
Closing the Gap Between Cancer Patients and Researchers: A Patient Advocate’s Perspective on GRASP
Patient advocate Marlena Murphy provides a patient’s perspective on GRASP.
The Past, Present, and Future of GRASP: Connecting Cancer Researchers, Clinicians, and Patient Advocates
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
Intense Neoadjuvant ADT May Not Improve Post-RP Outcomes in High-Risk Prostate Cancer
Neoadjuvant androgen deprivation therapy prior to prostate cancer surgery is feasible, investigators noted.
Underdosing in Patients With Cancer and Obesity: A Thing of the Past?
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...